Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enicepatide in Overweight or Obese Participants With Type 2 Diabetes Mellitus
NCT06628362Phase 2Completed
- Sponsor
- Carmot Therapeutics
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Peptides
- Countries
- 6
01
Overview
A Phase 2 trial of zilebesiran in type 2 diabetes mellitus (T2DM), obesity, sponsored by Carmot Therapeutics. Started Nov 2024; status: completed.
02
Drugs
zilebesiran
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06628362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628362.